Abstract
Evidence from numerous clinical trials has indicated that β-adrenoceptor blocking agents without intrinsic sympathomimetic activity increase plasma triglycerides and decrease high density lipoprotein cholesterol in patients with hypertension or coronary artery disease. There appears to be little or no difference between the nonselective and cardioselective drugs in this regard. In contrast, β blockers with intrinisc sympathomimetic activity and α 1 blockers appear not to have these effects. The changes induced by adrenoceptor-blocking agents in lipid and lipoprotein metabolism and their possible significance in relation to the pathogenesis of coronary artery disease are discussed.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call